Pharmaceuticals & Biotechnology
Valuation | |
|---|---|
| Market Cap | 1.29 kCr |
| Price/Earnings (Trailing) | 30.33 |
| Price/Sales (Trailing) | 4.02 |
| EV/EBITDA | 19.28 |
| Price/Free Cashflow | 33.38 |
| MarketCap/EBT | 26.48 |
| Enterprise Value | 1.49 kCr |
Fundamentals | |
|---|---|
Growth & Returns | |
|---|---|
| Price Change 1W | 5.2% |
| Price Change 1M | -4.2% |
| Price Change 6M | -22.4% |
| Price Change 1Y | -20.3% |
| 3Y Cumulative Return | -5.2% |
| 5Y Cumulative Return | -2.3% |
| 7Y Cumulative Return | 1.2% |
| 10Y Cumulative Return | 12.8% |
| Revenue (TTM) |
| 320.18 Cr |
| Rev. Growth (Yr) | 9.9% |
| Earnings (TTM) | 42.48 Cr |
| Earnings Growth (Yr) | -18.4% |
Profitability | |
|---|---|
| Operating Margin | 15% |
| EBT Margin | 15% |
| Return on Equity | 12.1% |
| Return on Assets | 6.29% |
| Free Cashflow Yield | 3% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | -19 Cr |
| Cash Flow from Operations (TTM) | 64.51 Cr |
| Cash Flow from Financing (TTM) | -51.72 Cr |
| Cash & Equivalents | 6.29 Cr |
| Free Cash Flow (TTM) | 43.92 Cr |
| Free Cash Flow/Share (TTM) | 51.63 |
Balance Sheet | |
|---|---|
| Total Assets | 675.18 Cr |
| Total Liabilities | 324.15 Cr |
| Shareholder Equity | 351.04 Cr |
| Current Assets | 203.72 Cr |
| Current Liabilities | 141.39 Cr |
| Net PPE | 239.62 Cr |
| Inventory | 65.87 Cr |
| Goodwill | 0.00 |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.31 |
| Debt/Equity | 0.59 |
| Interest Coverage | 3.25 |
| Interest/Cashflow Ops | 7.79 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 7 |
| Dividend Yield | 0.46% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | 0.00% |
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Technicals: Bullish SharesGuru indicator.
Profitability: Recent profitability of 13% is a good sign.
Balance Sheet: Strong Balance Sheet.
Growth: Poor revenue growth. Revenue grew at a disappointing -1% on a trailing 12-month basis.
Past Returns: Underperforming stock! In past three years, the stock has provided -5.2% return compared to 12.8% by NIFTY 50.
Smart Money: Smart money is losing interest in the stock.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Technicals: Bullish SharesGuru indicator.
Profitability: Recent profitability of 13% is a good sign.
Balance Sheet: Strong Balance Sheet.
Growth: Poor revenue growth. Revenue grew at a disappointing -1% on a trailing 12-month basis.
Past Returns: Underperforming stock! In past three years, the stock has provided -5.2% return compared to 12.8% by NIFTY 50.
Smart Money: Smart money is losing interest in the stock.
Investor Care | |
|---|---|
| Dividend Yield | 0.46% |
| Dividend/Share (TTM) | 7 |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 49.94 |
Financial Health | |
|---|---|
| Current Ratio | 1.44 |
| Debt/Equity | 0.59 |
Technical Indicators | |
|---|---|
| RSI (14d) | 51.65 |
| RSI (5d) | 100 |
| RSI (21d) | 43.11 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Sell |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal |
Summary of Hester Biosciences's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Understand Hester Biosciences ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| Rajiv Dinesh Gandhi | 10.48% |
| Sanjiv Dinesh Gandhi | 8.2% |
| Nina Rajiv Gandhi | 8.19% |
| Shaila Bhupendra Gandhi | 5.78% |
| Ravin Gandhi | 4.74% |
| Bela Gandhi | 4.71% |
| Bhupendra Vithaldas Gandhi | 4.68% |
Detailed comparison of Hester Biosciences against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| BAYERCROP | Bayer CropScience | 19.83 kCr | 6.24 kCr | -1.10% | -11.50% | 24.17 | 3.18 | - | - |
| AVANTIFEED | Avanti Feeds | 14.73 kCr |
Comprehensive comparison against sector averages
HESTERBIO metrics compared to Pharmaceuticals
| Category | HESTERBIO | Pharmaceuticals |
|---|---|---|
| PE | 30.58 | 33.84 |
| PS | 4.06 | 4.69 |
| Growth | -1 % | 8.9 % |
Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates through Poultry Healthcare, Animal Healthcare, and Petcare segments. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers livestock vaccines for goat pox, peste des petits ruminants, brucella abortus, contagious bovine pleuropneumonia, CCPP, and lumpy skin diseases; and diagnostic services. In addition, the company provides animal healthcare products, such as biosecurity solutions, therapeutic treatment, herbal supplements, homeopathic remedies, and feed supplements. Further, it offers various pet care products, including gut health solutions, NSAIDs, joint care formulations, parasiticides, coat nutrition, grooming aids, and anti-infective formulations. Additionally, the company provides seroprofiling kits; diagnostic labs for poultry flocks; and mastitis control programs for cattle; as well as engages in manufacturing and trading of goods. Hester Biosciences Limited was incorporated in 1987 and is headquartered in Ahmedabad, India.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
| Buy |
| SMA 20 Signal | Buy |
| SMA 50 Signal | Sell |
| SMA 100 Signal | Sell |
HESTERBIO vs Pharmaceuticals (2021 - 2026)
| Kuntal Hasmukhlal Shah | 3.17% |
| Biolink Healthcare Limited | 2.93% |
| Manish Jain | 2.88% |
| Anup Chandravadan Kapadia | 2.68% |
| Darshna Dinesh Kapadia | 1.81% |
| Vinay Shah | 1.28% |
| Sandeep Shantilal Gala | 1.24% |
| Manish Jain (HUF) | 1.24% |
| Jagrut Prataprai Gandhi | 1.18% |
| Manish Prataprai Gandhi | 1.18% |
| Investor Education and Protection Fund (IEPF) | 1.04% |
| Hester Coatings LLP | 0.75% |
| Hester Diagnostics Private Limited | 0.28% |
Distribution across major stakeholders
Distribution across major institutional holders
| 6.16 kCr |
| +23.90% |
| +49.90% |
| 23.81 |
| 2.39 |
| - |
| - |
| GODREJAGRO | Godrej Agrovet | 10.65 kCr | 10.08 kCr | -2.20% | -29.20% | 24.28 | 1.06 | - | - |
| SEQUENT | Sequent Scientific | 5.26 kCr | 1.67 kCr | +1.00% | +27.20% | 125.3 | 3.15 | - | - |
| 66 |
| 66 |
| 67 |
| 73 |
| 59 |
| 75 |
| Profit Before exceptional items and Tax | -21.4% | 12 | 15 | 19 | 2.44 | 12 | 11 |
| Total profit before tax | -21.4% | 12 | 15 | 19 | 2.44 | 12 | 11 |
| Current tax | 9% | 2.7 | 2.56 | 2.15 | 4.11 | 1.65 | 3.38 |
| Deferred tax | 159.3% | 1.51 | 0.14 | 0.74 | -1.91 | 0.31 | 0.1 |
| Total tax | 88.8% | 4.21 | 2.7 | 2.89 | 2.2 | 1.96 | 3.48 |
| Total profit (loss) for period | -36.1% | 9.31 | 14 | 17 | 1.54 | 11 | 8.39 |
| Other comp. income net of taxes | 33.5% | -0.41 | -1.12 | -0.18 | -0.17 | -0.37 | 0.21 |
| Total Comprehensive Income | -34.2% | 8.9 | 13 | 17 | 1.37 | 11 | 8.6 |
| Earnings Per Share, Basic | -37.3% | 10.94 | 16.85 | 20.33 | 1.82 | 13.41 | 9.86 |
| Earnings Per Share, Diluted | -37.3% | 10.94 | 16.85 | 20.33 | 1.82 | 13.41 | 9.86 |
| -3.6% |
| 55 |
| 57 |
| 48 |
| 39 |
| 33 |
| 37 |
| Finance costs | 6.8% | 5.37 | 5.09 | 6.5 | 2.47 | 3.95 | 5.03 |
| Depreciation and Amortization | -13.7% | 8.58 | 9.78 | 9.79 | 9.5 | 9.63 | 9.38 |
| Other expenses | 7.5% | 87 | 81 | 71 | 58 | 50 | 57 |
| Total Expenses | -1.6% | 249 | 253 | 215 | 171 | 150 | 131 |
| Profit Before exceptional items and Tax | 13.9% | 42 | 37 | 44 | 53 | 60 | 41 |
| Exceptional items before tax | - | 0 | 0 | 0 | 0 | -5.28 | 0 |
| Total profit before tax | 13.9% | 42 | 37 | 44 | 53 | 55 | 41 |
| Current tax | 15.9% | 11 | 9.63 | 11 | 14 | 16 | 12 |
| Deferred tax | -121.7% | -1.35 | -0.06 | 0.86 | -0.51 | -1.48 | -1.8 |
| Total tax | 4.1% | 9.92 | 9.57 | 12 | 14 | 15 | 10 |
| Total profit (loss) for period | 19.2% | 32 | 27 | 32 | 40 | 40 | 31 |
| Other comp. income net of taxes | -33.3% | -0.36 | -0.02 | 0.11 | -0.16 | 0.21 | -0.4 |
| Total Comprehensive Income | 15.4% | 31 | 27 | 32 | 39 | 40 | 31 |
| Earnings Per Share, Basic | 17.8% | 37.43 | 31.93 | 38.018 | 46.45 | 46.9 | 36.7 |
| Earnings Per Share, Diluted | 17.8% | 37.43 | 31.93 | 38.018 | 46.45 | 46.9 | 36.7 |
| 0% |
| 65 |
| 65 |
| 65 |
| 44 |
| 65 |
| 65 |
| Loans, non-current | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Total non-current financial assets | -2.9% | 68 | 70 | 68 | 48 | 70 | 69 |
| Total non-current assets | 0.8% | 364 | 361 | 351 | 345 | 339 | 330 |
| Total assets | -0.6% | 543 | 546 | 562 | 550 | 564 | 546 |
| Borrowings, non-current | -24% | 39 | 51 | 64 | 79 | 88 | 83 |
| Total non-current financial liabilities | -23.5% | 40 | 52 | 65 | 80 | 88 | 84 |
| Provisions, non-current | -15.9% | 2.16 | 2.38 | 2.52 | 2.26 | 1.98 | 1.72 |
| Total non-current liabilities | -10.1% | 99 | 110 | 125 | 139 | 145 | 117 |
| Borrowings, current | 17.3% | 62 | 53 | 74 | 54 | 74 | 81 |
| Total current financial liabilities | 3.4% | 93 | 90 | 108 | 94 | 114 | 123 |
| Provisions, current | 612.5% | 1.41 | 0.92 | 0.57 | 0.67 | 0.63 | 0.44 |
| Current tax liabilities | -113.1% | 0.64 | 3.75 | 2.15 | 2 | 2.64 | 3.39 |
| Total current liabilities | -1% | 96 | 97 | 112 | 98 | 120 | 136 |
| Total liabilities | -5.8% | 195 | 207 | 237 | 237 | 265 | 253 |
| Equity share capital | 0% | 8.51 | 8.51 | 8.51 | 8.51 | 8.51 | 8.51 |
| Total equity | 2.7% | 348 | 339 | 325 | 313 | 299 | 292 |
| Total equity and liabilities | -0.6% | 543 | 546 | 562 | 550 | 564 | 546 |
| 50% |
| 64 |
| 43 |
| 33 |
| 16 |
| - |
| - |
| Proceeds from sales of PPE | 22.3% | 0.27 | 0.06 | 0.03 | 0.18 | - | - |
| Purchase of property, plant and equipment | -4.8% | 21 | 22 | 73 | 91 | - | - |
| Interest received | -119.1% | 0.83 | 1.89 | 0.43 | 0.26 | - | - |
| Other inflows (outflows) of cash | 57.9% | 0.49 | -0.21 | 0.23 | -20.36 | - | - |
| Net Cashflows From Investing Activities | 7.4% | -19.04 | -20.63 | -71.96 | -110.58 | - | - |
| Proceeds from borrowings | -105.3% | 0 | 20 | 52 | 118 | - | - |
| Repayments of borrowings | -42.9% | 29 | 50 | 17 | 13 | - | - |
| Dividends paid | -28.1% | 5.17 | 6.8 | 8.51 | 8.51 | - | - |
| Interest paid | 0% | 13 | 13 | 9.87 | 1.36 | - | - |
| Other inflows (outflows) of cash | -104% | 0 | 26 | 24 | 0 | - | - |
| Net Cashflows from Financing Activities | -88.9% | -46.35 | -24.07 | 41 | 95 | - | - |
| Net change in cash and cash eq. | 16.3% | -1.42 | -1.89 | 2.77 | 0.28 | - | - |
Analysis of Hester Biosciences's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.
Last Updated: Dec 31, 2025
| Description | Share | Value |
|---|---|---|
| Poultry Healthcare | 66.0% | 51.1 Cr |
| Animal Healthcare | 34.0% | 26.3 Cr |
| Total | 77.4 Cr |